HEPATOLOGY RESEARCH

Risk model for predicting failure to rescue after hepatectomy: Cohort study of 1371 consecutive patients
Kimura J, Takagi K, Umeda Y, Fuji T, Yasui K, Yamada M, Nishiyama T, Nagai Y, Kanehira N and Fujiwara T
Although hepatectomy is a complex surgical procedure, its incidence among older patients has increased due to global aging. However, few studies have focused on the association between age and failure to rescue (FTR) posthepatectomy. This study aimed to investigate the association between age and FTR and develop a risk model for FTR following hepatectomy.
Unveiling the dynamics of hepatitis C virus transmission among injection drug users and men who have sex with men: A comprehensive study in Japan
Phyo Z, Tanaka S, Sugiyama A, Ko K, Takahashi K, Mirzaev UK, Akuffo GA, Chhoung C, Akita T, Kozuki M, Sakamori R and Tanaka J
In Japan, despite low nationwide hepatitis C (HCV) incidence, new infections among people who inject drugs (PWID) and men who have sex with men (MSM) hinder HCV elimination. We explored HCV transmission dynamics and screened HCV recombination within these populations.
Diagnostic accuracy of hepatitis E virus antibody tests: A comprehensive meta-analysis
Mirzaev UK, Yoshinaga Y, Baynazarov M, Ouoba S, Ko K, Phyo Z, Chhoung C, Akuffo GA, Sugiyama A, Akita T, Takahashi K, Fukuma S and Tanaka J
Hepatitis E virus (HEV) is a major global health issue, with an estimated 20 million infections annually. Although polymerase chain reaction (PCR) is the diagnostic gold standard due to its precision, it is expensive and technically demanding. Antibody tests offer a more practical and cost-effective alternative, although their accuracy can vary due to factors, such as test manufacturer, antigen composition, HEV genotype, and host immune status.
Distinct characteristics of MetALD (metabolic dysfunction-associated steatotic liver disease with greater alcohol consumption) in the general population
Yoon EL, Park H, Hong HP, Lee CM, Kim M, Kang BK and Jun DW
The term MetALD has been introduced to describe individuals who have metabolic dysfunction-associated steatotic liver disease (MASLD) with greater alcohol consumption, according to the new nomenclature for steatotic liver disease (SLD). This study aims to evaluate the prevalence and clinical characteristics of MetALD in the general population.
Guidelines for the diagnosis and treatment of idiopathic portal hypertension, extrahepatic portal obstruction, and Budd-Chiari syndrome in Japan
Furuichi Y, Kage M, Ohta M, Ohfuji S, Sasaki H, Hidaka H, Yoshida H, Kanto T, Kusano H, Akahoshi T, Obara K, Hashizume M, Kuniyoshi Y, Kawaguchi T, Okubo H, Ishikawa T, Hirooka M, Iwakiri Y, Nio M and Tanaka A
This is the English version of the guidelines for the diagnosis and treatment of idiopathic portal hypertension, extrahepatic portal obstruction, and Budd-Chiari syndrome, which were established and revised in 2018 by the Aberrant Portal Hemodynamics Study Group under the jurisdiction of the Ministry of Health, Labor, and Welfare in Japan. These guidelines are excerpts, and the full version consists of 86 clinical questions and explanations, totaling 183 pages in Japanese.
Efficacy of durvalumab plus tremelimumab treatment for unresectable hepatocellular carcinoma in immunotherapy era clinical practice
Hiraoka A, Tada T, Hirooka M, Kariyama K, Tani J, Atsukawa M, Takaguchi K, Itobayashi E, Fukunishi S, Tsuji K, Ishikawa T, Tajiri K, Ohama H, Toyoda H, Ogawa C, Nishimura T, Hatanaka T, Kakizaki S, Kawata K, Naganuma A, Kosaka H, Matono T, Kuroda H, Yata Y, Nishikawa H, Imai M, Aoki T, Ochi H, Tada F, Nakamura S, Nakamura Y, Nouso K, Morishita A, Itokawa N, Okubo T, Arai T, Tsutsui A, Nagano T, Tanaka K, Tanaka H, Koshiyama Y, Kanayama Y, Noritake H, Enomoto H, Kaibori M, Hiasa Y, Kudo M, Kumada T and
Since the development of tremelimumab plus durvalumab (Dur/Tre) for unresectable hepatocellular carcinoma (uHCC), it has been used as not only an initial but also later line treatment in clinical practice. This study aimed to elucidate clinical prognostic factors for progression-free survival (PFS) in Dur/Tre treatment cases.
The role of the nervous system in liver diseases
Mravec B and Szantova M
The nervous system significantly participates in maintaining homeostasis, and modulating repair and regeneration processes in the liver. Moreover, the nervous system also plays an important role in the processes associated with the development and progression of liver disease, and can either potentiate or inhibit these processes. The aim of this review is to describe the mechanisms and pathways through which the nervous system influences the development and progression of liver diseases, such as alcohol-associated liver disease, nonalcoholic fatty liver disease, cholestatic liver disease, hepatitis, cirrhosis, and hepatocellular carcinoma. Possible therapeutic implications based on modulation of signals transduction between the nervous system and the liver are also discussed.
Refining the predictive utility of aspartate aminotransferase to platelet ratio index in nonalcoholic fatty liver disease patients with COVID-19
Matsumoto K and Nishida T
Body mass index of 23 or greater is relevant to hepatic steatosis and fibrosis in patients with harmful alcohol use
Kakisaka K, Watanabe T, Yoshida Y, Abe H, Yusa K, Sasaki T, Fujiwara Y, Abe T, Suzuki A, Endo K, Oikawa T, Sawara K, Miyasaka A, Kuroda H and Matsumoto T
Steatotic liver disease, characterized by a combination of metabolic dysfunction, alcohol use, or specific etiologies, is a leading cause of chronic liver disease. However, the role of metabolic dysfunction in chronic liver disease with harmful alcohol use remains unclear. This study aimed to investigate factors associated with hepatic steatosis and fibrosis in patients with harmful alcohol use.
Distribution of Fibrosis-4 index and vibration-controlled transient elastography-derived liver stiffness measurement for patients with metabolic dysfunction-associated steatotic liver disease in health check-up
Ogawa Y, Tomeno W, Imamura Y, Baba M, Ueno T, Kobayashi T, Iwaki M, Nogami A, Kessoku T, Honda Y, Notsumata K, Fujikawa H, Kaai M, Imajo K, Kawanaka M, Hyogo H, Hisatomi M, Takeuchi M, Hakamada T, Honda T, Tatsuta M, Morishita A, Mikami S, Furuya K, Manabe N, Kamada T, Kawaguchi T, Yoneda M, Saito S and Nakajima A
The multisociety consensus nomenclature has introduced steatotic liver disease (SLD) with diverse subclassifications, which are metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD), alcohol-associated liver disease (ALD), specific etiology, and cryptogenic. We investigated their prevalence, as per the new definition, in individuals undergoing health check-ups. Additionally, we analyzed the distribution of Fibrosis-4 (FIB-4) index and vibration-controlled transient elastography (VCTE)-derived liver stiffness measurement (LSM) for MASLD.
Persistent acute kidney injury: Postoperative impact and predictors in patients undergoing liver resection
Doi S, Yasuda S, Nagai M, Nakamura K, Matsuo Y, Terai T, Kohara Y, Sakata T and Sho M
Persistent acute kidney injury (AKI) has not been investigated in patients undergoing liver resection. We aimed to identify the predictors of persistent AKI, its effect on postoperative outcomes and long-term renal function in patients following liver resection, and its impact on survival in patients with hepatocellular carcinoma (HCC).
c-Met inhibitor upregulates E-cadherin, which is lost in portal vein tumor thrombus of hepatocellular carcinoma
Abe S, Inagaki Y, Kokudo T, Miyata A, Nishioka Y, Ichida A, Kaneko J, Akamatsu N, Kawaguchi Y and Hasegawa K
Portal vein tumor thrombus (PVTT) in hepatocellular carcinoma (HCC) is an essential therapeutic and prognostic factor. E-cadherin plays a crucial role in adhesive properties and intercellular interaction in various cancer tissues, including HCC, but the expression profile and functional contribution of E-cadherin in PVTT remain unknown. This study aimed to analyze the expression of E-cadherin in the main tumor tissue and PVTT tissue of HCC, and evaluate the functional roles of E-cadherin in PVTT formation.
Real-world trends in acute viral hepatitis in Japan: A nationwide questionnaire-based survey
Okushin K, Kanto T, Korenaga M, Ikeuchi K, Kishida T, Kado A, Fujishiro M, Tsutsumi T, Takura T, Yotsuyanagi H and
The actual incidence of acute viral hepatitis in Japan remains unclear. We aimed to investigate trends in the incidence of acute hepatitis B and C infections in Japan.
Prognostic performance of a two-step method using the Fibro-Scope system for metabolic dysfunction-associated steatotic liver disease
Seko Y, Yamaguchi K, Shima T, Tanaka S, Shirono T, Takahashi Y, Takeuchi K, Kataoka S, Moriguchi M, Okanoue T and Itoh Y
Fibro-Scope is an artificial intelligence/neural network system for the noninvasive diagnosis of hepatic fibrosis in patients with metabolic dysfunction-associated steatotic liver disease. We aimed to examine the diagnostic performance of a two-step method that used the Fibrosis-4 (FIB-4) index and Fibro-Scope system for the assessment of Japanese patients with metabolic dysfunction-associated steatotic liver disease.
Optimal transplant strategy of pediatric liver transplantation for fibropolycystic liver disease: Multicenter retrospective study in Japan
Uchida H, Inui A, Okamoto T, Yasui T, Honda M, Mizuta K, Bessho K, Okajima H, Ueno T, Matsuura T, Okada N, Sakamoto S and Kasahara M
To assess the preoperative disease characteristics and indications for living donor liver transplantation (LDLT), complications, patient survival, and prognosis after LDLT for fibropolycystic liver disease (FLD) in children.
Characteristics of diabetes mellitus patients with nonviral chronic liver disease who developed hepatocellular carcinoma
Sasaki K, Kawanaka M, Tomiyama Y, Takaki A, Otsuka M, Ikeda F, Yoshioka N, Kaneto H, Wada J, Fukuda T, Hino K and Nishina S
Type 2 diabetes mellitus (T2DM) is a well-known risk factor for hepatocellular carcinoma (HCC). However, HCC is often diagnosed at an advanced stage in patients with diabetes because of the lack of the best criteria for surveillance candidates. The aim of this study was to identify risk factors for HCC development in patients with diabetes with nonviral chronic liver disease.
Fatty liver index and somatic composition in subjects receiving medical health checkup
Ushiro K, Matsui M, Fukuda A, Onishi S, Nishikawa T, Asai A, Kim SK and Nishikawa H
To elucidate the relationship between fatty liver index (FLI) and somatic composition among health checkup recipients (4533 men and 4877 women).
Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs
Suzuki T, Matsuura K, Inoue T, Kawamura H, Fujiwara K, Kataoka H and Tanaka Y
Several studies have reported that chronic hepatitis B (CHB) patients with low hepatitis B surface antigen (HBsAg) levels (100 or 10 IU/mL) at the cessation of nucleot(s)ide analogs (NA) have a favorable prognosis. In this retrospective study, we evaluated the duration of NA treatment and the factors associated with achieving these low HBsAg levels. We also examined the relationship between HBsAg and hepatitis B core-related antigen (HBcrAg) levels at the time of NA discontinuation and subsequent clinical outcomes.
Time trend of outcomes according to systemic therapy for patients with unresectable hepatocellular carcinoma: A single-institution study
Uchikawa S, Kawaoka T, Murakami S, Miura R, Shirane Y, Johira Y, Kosaka M, Fujii Y, Fujino H, Ono A, Murakami E, Miki D, Hayes CN, Tsuge M and Oka S
We have been able to use molecular targeted agents for unresectable hepatocellular carcinoma since 2009, and immune checkpoint inhibitors have been approved in recent years. We assessed the efficacy of systemic therapy in Hiroshima University Hospital by each era.
New nomenclature and subclassification of steatotic liver disease and loss of skeletal muscle mass: A longitudinal cohort study
Kim A, Kang D, Choi SC, Sinn DH and Gwak GY
Identifying risk factors for sarcopenia is important due to its significant effect on health. The association between sarcopenia and the newly proposed steatotic liver disease (SLD) and its subclassification has largely been unexplored.
Factors involved in gastroesophageal varix-related events in patients with hepatitis C virus-related compensated and decompensated cirrhosis after direct-acting antiviral therapy
Tahata Y, Hikita H, Mochida S, Enomoto N, Kawada N, Ido A, Miki D, Kurosaki M, Yoshiji H, Sakamori R, Kuroda H, Yatsuhashi H, Yamashita T, Hiasa Y, Kato N, Miyaaki H, Ueno Y, Itoh Y, Matsuura K, Takami T, Asahina Y, Suda G, Akuta N, Tateishi R, Nakamoto Y, Kakazu E, Terai S, Shimizu M, Miyazaki M, Nozaki Y, Sobue S, Yano H, Miyaki T, Moriuchi A, Hori T, Shirai K, Murai K, Saito Y, Kodama T, Tatsumi T, Yamada T and Takehara T
The incidence of and factors involved in gastroesophageal varix-related events in hepatitis C virus-related cirrhosis patients, including decompensated cirrhosis, after direct-acting antiviral therapy are unclear.